ARCHIVES

FDA Proposes New User Fees for Generics and Biosimilar Products

This article is from The Cancer Letter archive.

Vol. 38 No. 03 | January 20, 2012

Download PDF Visit The Full Archive

Related Articles

ODAC Recommendation for Pertuzumab Signals FDA’s Resolve In Granting Accelerated Approvals

September 20, 2013

New Grants Awarded In Tobacco Research

February 17, 1978

Synar Bill Provides FDA Regulation Of Tobacco Products

March 4, 1994

PSA Velocity Poor Predictor Of Prostate Cancer Occurrence

March 25, 2011

Trials Approved by NCI CTEP For The Month of February

February 24, 2012

Prime Contract Subcontract Opportunities

January 24, 1975